Background: Cyclin B1 has an important role in the G 2 -M phase transition of the cell cycle. Wee1 delays mitosis by suppressing the activity of the Cyclin B1/cdc2 complex. The objective of the present study was to elucidate the clinicopathological and prognostic significance of Cyclin B1 and Wee1 expression in non-smallcell lung cancer (NSCLC).
Introduction
Cyclin and cyclin-dependent kinase complexes play an important role in control of the cell cycle [1] . Cyclin B1/cdc2 complex has a role as a maturation/mitosis-promoting factor in the G 2 -M phase transition during the cell cycle [1] . Thus, dysregulation of the expression of Cyclin B1 may be involved in uncontrolled cell growth and malignant transformation. Overexpression of Cyclin B1 has been reported in various malignant tumors [2] [3] [4] [5] [6] and has been shown to be a poor prognostic factor in some of them [4] [5] [6] . The activity of Cyclin B1/cdc2 complex is inhibited by phosphorylation of the tyrosine 15 residue (Tyr15) on cdc2 [7] . The phosphorylation of Tyr15 is achieved by Wee1 kinase, a nuclear protein that delays mitosis until the completion of DNA replication in cells with DNA damage [8] . In colon carcinoma cells, Wee1 expression is reduced, suggesting that it acts as a tumor suppressor [9] .
We carried out immunohistochemical analysis to assess the clinicopathological and prognostic significance, and the interrelationship, of Cyclin B1 and Wee1 expression. Furthermore, we examined by differential PCR analysis whether patients with nonsmall-cell lung cancer (NSCLC) have amplification or deletion of the Cyclin B1 and Wee1 genes.
Patients and methods

Patients
The study focused on 79 patients with NSCLC who had undergone lobectomy with lymph node dissection between 1989 and 2001 at the Department of Surgery I, Gunma University Faculty of Medicine. The lung cancers were classified according to the TNM Classification of the International Union Against Cancer, 5th edition [10] . Patients who had received irradiation or chemotherapy prior to surgery, or for whom follow-up had been considered inadequate, were not included in the study. The pathological staging of this group was: stage I in 53, stage II in nine and stage III in 17 cases. Among the 79 patients, 16 had disease recurrence after surgery.
Immunohistochemistry
Immunohistochemical staining was performed according to a previously described method [11] . The tissue sections were placed in 10 mM citrate buffer (pH 6.0 for Cyclin B1 and Ki-67, pH 7.0 for Wee1) and heated in an autoclave oven. The sections were incubated with either normal rabbit serum for the Cyclin B1, Ki-67 and proliferating cell nuclear antigen (PCNA) samples, or 4% Block Ace Solution (Dainippon Pharmaceutical Corp., Osaka, Japan) for the Wee1 samples. The sections were incubated with anti-Cyclin B1 monoclonal antibody (Novocastra Laboratories, Newcastle-upon-Tyne, UK) at a dilution of 1:200, and with anti-Wee1 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Ki-67 monoclonal antibody (DAKO, Glostrup, Denmark) and anti-PCNA monoclonal antibody (DAKO) all at a dilution of 1:100.
When >15% of tumor cells were immunoreactive [6] , the sample was regarded as Cyclin B1-positive. The Wee1 labeling index defined the percentage of nuclear-stained tumor cells, and was classified as follows: 0 = <10%, 1+ = 10-30%, 2+ = 30-50% and 3+ = >50% of cell staining. Because this division was considered the most reliable prognostic indicator, we regarded a specimen with a score 0 or 1+ as negative. The Ki-67 proliferative index (KiIndex) and PCNA labeling index (PCNA-LI) were defined as the percentages of nuclear-stained tumor cells.
Differential PCR analysis for the expression of Cyclin B1 and Wee1 genes
We studied 18 of the 79 patients whose specimens were subjected to immunohistochemical analysis. Total DNA was extracted from each fresh-frozen human lung tumor tissue and normal tissue using a DNeasy Tissue Kit (Qiagen, Valencia, CA, USA). For differential PCR analysis, a 150-bp fragment of the Cyclin B1 gene was co-amplified with an 82-bp fragment of the interferon-γ (IFNG) gene as an internal control [12] . Moreover, the same analysis was performed for a 440-bp fragment of the Wee1 gene and the IFNG gene. Specific primers used were as follows: 5′-CCTGCAAATGCCTGGTT-TAT-3′ and 5′-CATGCTTCGATGTGGCATAC-3′ for Cyclin B1; 5′-ACT-GATAGAATCCAGTTTGC-3′ and 5′-ATGCAATGCCTACAAAGTGC-3′ for Wee1 [13] ; and 5′-GCAGAGCCAAATTGTCTCCT-3′ and 5′-GGTCTC-CACACTCTTTTGGA-3′ for IFNG [12] . Differential PCR was performed by 25 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 1 min and extension at 72°C for 1 min.
The PCR products were electrophoresed in 3% agarose gel with ethidium bromide and autoradiographed by Fluor-S MAX2 MultiImager (Bio-Rad, Hercules, CA, USA). Analysis of gene density was performed using Quantity One v. 4.2.1 software (Bio-Rad). The ratio of the total target gene density relative to the total control gene density was calculated for each sample. Furthermore, using this result we analyzed the ratio of lung tumor tissue relative to normal tissue (T/N ratio) in each patient.
Statistical analysis
Statistical analysis was performed according to a previously described method [11] , and Cox's proportional hazards model for risk ratio was used to assess the results of multivariate survival analysis. Differences were considered to be statistically significant at P <0.05.
Results
Cyclin B1 expression was predominantly located with in the cytoplasm of the tumor cells ( Figure 1A ). Positive expression of Cyclin B1 was observed in 13 out of 79 patients (16.5%). Positive staining for Wee1 was observed in the nuclei of the tumor cells ( Figure 1B) . Absence of Wee1 expression was seen in 52 patients (65.8%). The relationship between the expression of Cyclin B1 and Wee1 and the clinicopathological features of NSCLC, including Ki-Index and PCNA-LI values, is shown in Table 1 . Poorly differentiated tumors showed significantly higher Cyclin B1 expression than well and moderately differentiated tumors (P = 0.0423). Furthermore, there was a significant correlation between Cyclin B1 expression and vascular invasion (P = 0.001). Both the KiIndex and PCNA-LI values were significantly higher in Cyclin B1-positive tumors than negative tumors (P <0.0001 and P <0.0001, respectively). There was no significant correlation between Wee1 expression and the various clinicopathological factors. The KiIndex and PCNA-LI values tended to be higher in Wee1-negative tumors than positive tumors. No significant correlation was recognized between the expression of Cyclin B1 and Wee1 ( Table 2) .
The patients with Wee1-negative tumors had a significantly higher recurrence rate than those with Wee1-positive tumors (Table 3 ; P = 0.0084). The postoperative survival rate of patients with Cyclin B1-positive tumors was significantly lower than that of patients with Cyclin B1-negative tumors (Figure 2A ; P = 0.0068). The postoperative survival rate of patients with Wee1-negative tumors was also significantly lower than that of patients with Wee1-positive tumors ( Figure 2B ; P = 0.0457). The result of the multivariate analysis is shown in Table 4 . This result suggests that the expression of Cyclin B1 (P = 0.0244) and Wee1 (P = 0.0444) are both significant prognostic factors.
The mean value of the T/N ratio in the Cyclin B1 gene and the Wee1 gene was 0.97 ± 0.17 and 0.95 ± 0.18, respectively. Therefore, there appeared to be no difference in the expression of Cyclin B1 and Wee1 genes between lung tumor tissue and normal tissue. 
Discussion
In this study, overexpression of Cyclin B1 was associated with grade of differentiation and vascular invasion, and also with significantly higher Ki-Index and PCNA-LI values. The expression of Ki-67 and PCNA are generally well established as markers of cell proliferation and malignant potential in NSCLC [14, 15] . Thus, our data suggest that overexpression of Cyclin B1 may indicate an increased malignant potential, and may be a significant prognostic indicator in patients with NSCLC. Soria et al. [6] reported that there was a clinical relationship between overexpression of Cyclin B1 and early-stage NSCLC, particularly the squamous subtype. Some investigators have suggested that overexpression of Cyclin B1 is associated with aggressive tumor behavior, and that this is a useful prognostic marker in patients with squamous cell carcinoma [4] [5] [6] . However, other authors have reported that overexpression of Cyclin B1 is associated with less aggressive tumor behavior, and is not a useful prognostic parameter in patients with adenocarcinoma [2, 3] . Although >70% of the patients in our study had adenocarcinoma, our data suggest that expression of Cyclin B1 is a significant prognostic indicator. Although the data supporting this argument are not shown, overexpression of Cyclin B1 was associated with a poor prognosis in Table 1 . The correlation between clinicopathalogical factors and Cyclin B1 and Wee1 expression in patients with NSCLC NSCLC, non-small-cell lung cancer; Ki-Index, Ki-67 proliferative index; PCNA-LI, proliferating cell nuclear antigen labeling index.
Parameter n Cyclin B1 Wee1
Age (years) (mean ± SD) 65.7 ± 9.9 64. patients with adenocarcinoma. The reason that other reports have differed from ours may be due to organ specificity, disease stage or heterogeneity. About one-third of the patients in this study were at an advanced stage, and overexpression of Cyclin B1 was observed more frequently in stage III tumors. Similar to a previous study [16] , our data also indicate that patients with NSCLC have no amplification or deletion of the Cyclin B1 gene. This result suggests that Cyclin B1 expression at the protein level may be regulated by other mechanisms, for example transcription, DNA methylation or translation, and not by gene expression at the DNA level. The activity of the Cyclin B1/cdc2 complex is negatively controlled by Wee1 kinase activity [8] . Thus, loss of Wee1 confers an advantage to neoplastic cells by allowing faster progression through the cell cycle. In this study, absence of Wee1 expression was observed immunohistochemically in about two-thirds of the NSCLC patients. The reduction in Wee1 expression was associated with a poorer prognosis and a higher recurrence rate. These tumors also tended to have higher Ki-Index and PCNA-LI values. This suggests that Wee1 may be only a weak suppressor of tumor progression in NSCLC. As for Cyclin B1, Wee1 expression at the protein level may be regulated by other mechanisms, and not by gene expression at the DNA level.
In conclusion, we suggest that assessment of Cyclin B1 expression could be useful for evaluating tumor progression and prognosis in NSCLC patients. Loss of Wee1 expression may play a role in promoting tumor aggressiveness, and may be a useful prognostic indicator. 
